Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists

Journal of Clinical Oncology

Volumn 31, Issue 9, 2013, Pages 1134-1139

  Conti, Rena M ^a   Bernstein, Arielle C ^a   Villaflor, Victoria M ^a   Schilsky, Richard L ^a   Rosenthal, Meredith B ^b   Bach, Peter B ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b HARVARD UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; DOCETAXEL; GEMCITABINE; PACLITAXEL; PEMETREXED; RITUXIMAB; TRASTUZUMAB;

ARTICLE; DRUG COST; DRUG INDICATION; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL;

COHORT STUDIES; DATABASES, FACTUAL; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; OFF-LABEL USE; PHARMACY; UNITED STATES;

EID: 84875983431     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.7252     Document Type: Article

References (38)

1. Edwards BK, Brown ML, Wingo PA, et al: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407-1427, 2005 (Pubitemid 41520077)
2. MEDPAC: Report to Congress: Variation and innovation in Medicare. 2006. http://www.medpac.gov/publications/congressional-reports/June03-Ch9.pdf
3. Schrag D: The price tag on progress: Chemotherapy for colorectal cancer. N Engl J Med 351:317-319, 2004 (Pubitemid 38944397)
4. Yabroff KR, Lamont EB, Mariotto A, et al: Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100:630-641, 2008
5. Aitken ML, Berndt ER, Cutler DM: Prescription drug spending trends in the US: Looking beyond the turning point. Health Affairs 28:151-160, 2009
6. Mayer RJ: Targeted therapy for advanced colorectal cancer: More is not always better. N Engl J Med 360:623-625, 2009
7. Nadler E, Eckert B, Neumann PJ: Do oncologists believe new cancer drugs offer good value? Oncologist 11:90-95, 2006 (Pubitemid 43261756)
8. Bach PB: Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
9. Malin JL, Schneider EC, Epstein AM, et al: Results of the National Initiative for Cancer Care Quality: How can we improve the quality of cancer care in the United States? J Clin Oncol 24:626-634, 2006 (Pubitemid 46630426)
10. Shrank WH, Asch SM, Adams J, et al: The quality of pharmacologic care for adults in the United States. Med Care 44:936-945, 2006 (Pubitemid 44454571)
11. Chassin MR, Galvin RW: The urgent need to improve health care quality: Institute of Medicine National Roundtable on Health Care Quality. JAMA 280:1000-1005, 1998
12. Laetz T, Silberman G: Reimbursement policies constrain the practice of oncology. JAMA 266: 2996-2999, 1991 [Erratum: 267: 3287, 1992]
13. Giordano SH, Lin YL, Kuo YF, et al: Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30:2232-2239, 2012
14. Radley DC, Finkelstein SN, Stafford RS: Offlabel prescribing among office-based physicians. Arch Intern Med 166:1021-1026, 2006
15. Briesacher BA, Limcangco MR, Simoni-Wastila L, et al: The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 165: 1280-1285, 2005 (Pubitemid 40989593)
16. Goulding MR: Inappropriate medication prescribing for elderly ambulatory care patients. Arch Intern Med 164:305-312, 2004 (Pubitemid 38176470)
17. Sebalt RJ, Petrie A, Goldsmith CH, Marenette MA: Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: Results from the CANOAR study. Am J Manage Care 10:742-750, 2005 (Pubitemid 39518520)
18. Naunton M, Peterson GM, Bleasel MD: Overuse of proton pump inhibitors. J Clin Pharm Ther 25:333-340, 2000 (Pubitemid 32002877)
19. Conti RM, Busch AB, Cutler DM: The appropriate use of antidepressants in 2005. Psychiatr Serv 62:703, 2011
20. Levêque D: Off-label use of anticancer drugs. Lancet Oncol 9:1102-1107, 2008
21. American Society of Clinical Oncology: Reimbursement for cancer treatment: Coverage of offlabel drug indications. J Clin Oncol 24:3206-3208, 2006
22. Smith BD, Pan IW, Shih YC, et al: Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 103:798-809, 2011
23. Azoulay P: Do pharmaceutical sales respond to scientific evidence? J Econ Manage Str 11:551-594, 2002
24. Azzoli CG, Temin S, Aliff T, et al: 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29:3825-3831, 2011
25. Nemeroff CB, Kalali A, Keller MB, et al: Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 64:466-472, 2007 (Pubitemid 46556464)
26. Hoffman JM, Li E, Doloresco F, et al: Projecting future drug expenditures: 2012. Am J Health Syst Pharm 69:405-421, 2012
27. United States General Accounting Office: OffLabel Drugs: Reimbursement Policies Constrain Physicians in Their Choice of Cancer Therapies. September 1991: GAO/PEMD-91-14. http://archive.gao.gov/d18t9/144933.pdf
28. Conti RM, Bernstein A, Meltzer DO: How do initial signals of quality influence the diffusion of new medical products? The case of new cancer treatments. Adv Health Econ Health Serv Res 23: 123-148, 2012.
29. Van Allen EM, Miyake T, Gunn N, et al: Off-label use of rituximab in a multipayer insurance system. J Oncol Pract 7:76-79, 2011
30. Abrams TA, Brightly R, Mao J, et al: Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or stage III colon cancer. J Clin Oncol 29:3255-3262, 2011
31. DRUGDEX System: CD-ROM, version 5.1. Thomson Micromedex
32. Recent developments in Medicare coverage of off-label cancer therapies. J Oncol Pract 5:18-20, 2009
33. Roche: 2010 Annual Report. Basel, Switzerland: F. Hoffmann-La Roche Ltd, 2010. www.roche.com/gb10e.pdf
34. Walton SM, Schumock GT, Lee KV, et al: Prioritizing future research on off-label prescribing: Results of a quantitative evaluation. Pharmacotherapy 28:1443-1452, 2008
35. McKinney R, Abernethy AP, Matchar DB, et al: White paper: Potential conflict of interest in the production of drug compendia, project ID: CMPE 1207. Agency for Healthcare Research and Quality, Technology Assessment Report, April 2009
36. Abernethy AP, Hammond JM, Hubbard ML, Patwardham MB, et al: Compendia for coverage of off-label uses of drugs and biologics in an anticancer chemotherapeutic regimen. Agency for Healthcare Research and Quality, Technology Assessment Report, May 2007
37. Peppercorn J, Burstein H, Miller FG, et al: Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol 26:5994-6000, 2008
38. Selby JV, Beal AC, Frank L: The patient-centered outcomes research institute (PCORI) national priorities for research and initial research agenda. JAMA 307:1583-1584, 2012